← Back to headlines
Amylyx Pharmaceuticals Completes Avexitide Phase 3 Lucidity Trial Enrollment
Amylyx Pharmaceuticals (AMLX) has successfully completed the enrollment for its Avexitide Phase 3 Lucidity Trial.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
